IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL att erhålla royalties. Avtalet har formellt undertecknats av Immunotech, ett dotterbolag till Beckman Coulter.
Läs pressmeddelandet här.
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF. Read the press release here
Redeye has today released a new research note on the previous analysis of Arocell. The full report can be found on their website. Link to Redeye's new research note.
Time: 10.00 - 12.00 CEST, June 15th 2020 On June 15, Arocell AB provides a live broadcast business update with subsequent question time led by Redeye’s analyst Oscar Bergman. CEO Michael Brobjer, together with parts of the management team, will among other things...
